Precocious puberty

Current Opinion in Obstetrics and Gynecology

Volumn 26, Issue 5, 2014, Pages 332-338

  Neely, E Kirk ^a   Crossen, Stephanie S ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gonadotropin releasing hormone; Histrelin; Leuprolide; Precocious puberty; Thelarche

Indexed keywords

BUSERELIN; DEPOT LEUPROLIDE; DEPOT TRIPTORELIN; GONADORELIN DERIVATIVE; GOSERELIN; HISTRELIN; KISSPEPTIN; LEUPRORELIN; LUTEINIZING HORMONE; NEUROKININ B; TRIPTORELIN; UNCLASSIFIED DRUG; GONADORELIN;

BODY COMPOSITION; BODY HEIGHT; BONE; CENTRAL PRECOCIOUS PUBERTY; COHORT ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GNRHA STIMULATION TEST; HUMAN; IMAGING; MENARCHE; ONSET AGE; OVARY FUNCTION; PRECOCIOUS PUBERTY; PREMATURE ADRENARCHE; PRIORITY JOURNAL; REPRODUCTION; REVIEW; SOCIAL PSYCHOLOGY; ANALOGS AND DERIVATIVES; BODY WEIGHT; BONE DENSITY; CHILD; DRUG EFFECTS; FEMALE; INCIDENCE; PATHOPHYSIOLOGY; PUBERTY, PRECOCIOUS; SEXUAL MATURATION;

BODY HEIGHT; BODY WEIGHT; BONE DENSITY; CHILD; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INCIDENCE; PUBERTY, PRECOCIOUS; SEXUAL MATURATION;

EID: 84925792524     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000099     Document Type: Review

References (76)

1. Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab 2013;98:2198-2207. A good recent review.
2. Willemsen RH, Elleri D, Williams RM, et al. Pros and cons of GnRHa treatment for early puberty in girls. Nat Rev Endocrinol 2014;10:352-363. An expert discussion of the decision whether or not to treat with GnRH analogs.
3. Sorensen K, Mouritsen A, Aksglaede L, et al. Recent secular trends in pubertal timing: implications for evaluation and diagnosis of precocious puberty. Horm Res Paediatr 2012;77:137-145. A sophisticated discussion of the onset of puberty controversy.
4. Topaloglu AK, Tello JA, Kotan LD, et al. Inactivating KiSS1 mutation and hypogonadotropic hypogonadism. N Engl J Med 2012;366:629-635.
5. Young J, Bouligand J, Francou B, et al. TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. J Clin Endocrinol Metab 2010;95:2287-2295.
6. De Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA 2003;100:10972-10976.
7. Irwig MS, Fraley GS, Smith JT, et al. Kisspeptin activation of gonadotropin releasing hormone neurons and regulation of KiSS-1 mRNA in the male rat. Neuroendocrinology 2004;80:264-272.
8. Messager S, Chatzidaki EE, Ma D, et al. Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. Proc Natl Acad Sci USA 2005;102:1761-1766.
9. Shahab M, Mastronardi C, Seminara SB, et al. Increased hypothalamic GPR54 signaling: a potential mechanism for initiation of puberty in primates. Proc Natl Acad Sci USA 2005;102:2129-2134.
10. Smith JT, Dungan HM, Stoll EA, et al. Differential regulation of KiSS-1 mRNA expression by sex steroids in the brain of the male mouse. Endocrinology 2005;146:2976-2984.
11. Topaloglu AK, Reimann F, Guclu M, et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nat Genet 2009;4:354-358.
12. Young J, George JT, Tello JA, et al. Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications. Neuroendocrinology 2013;97:193-202. This study demonstrates the interaction and relative positions of kisspeptin and neurokinin B in the neuroendocrine cascade-regulating GnRH secretion.
13. Millar RP, Newton CL. Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat Rev Endocrinol 2013;9:451-466.
14. Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics 1997;99:505-512.
15. Biro FM, Greenspan LC, Galvez MP, et al. Onset of breast development in a longitudinal cohort. Pediatrics 2013;132:1019-1027. The most recent publication from a series of studies redefining the onset of thelarche.
16. Euling SY, Herman-Giddens ME, Lee PA, et al. Examination of US pubertytiming data from 1940 to 1994 for secular trends: panel findings. Pediatrics 2008;121(Suppl 3):S172-S191.
17. Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 1999;104:936-941.
18. McDowell MA, Brody DJ, Hughes JP. Has age at menarche changed? Results from the National Health and Nutrition Examination Survey (NHANES) 1999-2004. J Adolesc Health 2007;40:227-231.
19. Midyett LK, Moore WV, Jacobson JD. Are pubertal changes in girls before age 8 benign? Pediatrics 2003;111:47-51.
20. Mogensen SS, Aksglaede L, Mouritsen A, et al. Diagnostic work-up of 449 consecutive girls who were referred to be evaluated for precocious puberty. J Clin Endocrinol Metab 2011;96:1393-1401.
21. Mogensen SS, Aksglaede L, Mouritsen A, et al. Pathological and incidental findings on brain MRI in a single-center study of 229 consecutive girls with early or precocious puberty. PLoS One 2012;7:e29829.
22. Aksglaede L, Sorensen K, Petersen JH, et al. Recent decline in age at breast development: the Copenhagen Puberty Study. Pediatrics 2009;123:e932-e939.
23. Susman EJ, Houts RM, Steinberg L, et al., Eunice Kennedy Shriver NICHD Early Child Care Research Network. Longitudinal development of secondary sexual characteristics in girls and boys between ages 9 1/2 and 15 1/2 years. Arch Pediatr Adolesc Med 2010;164:166-173.
24. Euling SY, Selevan SG, Pescovitz OH, Skakkebaek NE. Role of environmental factors in the timing of puberty. Pediatrics 2008;121:S167-S171.
25. Ibanez L, Diaz R, Lopez-Bermejo A, Marcos MV. Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism. Rev Endocr Metab Disord 2009;10:63-76.
26. Ibanez L, Lopez-Bermejo A, Diaz M, et al. Early metformin therapy to delay menarche and augment height in girls with precocious pubarche. Fertil Steril 2011;95:727-730.
27. Williams RM, Ward CE, Hughes IA. Premature adrenarche. Arch Dis Child 2012;97:250-254.
28. Brown DB, Loomba-Albrecht LA, Bremer AA. Sexual precocity and its treatment. World J Pediatr 2013;9:103-111.
29. Pescovitz OH, Hench KD, Barnes KM, et al. Premature thelarche and central precocious puberty: the relationship between clinical presentation and the gonadotropin response to luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 1988;67:474-479.
30. Ibanez L, Potau N, Zampolli M, et al. Use of leuprolide acetate response patterns in the early diagnosis of pubertal disorders: comparison with the gonadotropinreleasing hormone test. J Clin Endocrinol Metab 1994;78:30-35.
31. De Vries L, Guz-Mark A, Lazar L, et al. Premature thelarche: age at presentation affects clinical course but not clinical characteristics or risk to progress to precocious puberty. J Pediatr 2010;156:466-471.
32. Zacharin M. The spectrum of McCune Albright syndrome. Pediatr Endocrinol Rev 2007;4:412-418.
33. Eugster EA. Peripheral precocious puberty: causes and current management. Horm Res 2009;71:64-67.
34. Feuillan P, Calis K, Hill S, et al. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab 2007;92:2100-2106.
35. Elks CE, Perry JR, Sulem P, et al. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet 2010;42:1077-1085.
36. Soriano-Guillen L, Corripio R, Labarta JI, et al. Central precocious puberty in children living in Spain: incidence, prevalence, and influence of adoption and immigration. J Clin Endocrinol Metab 2010;95:4305-4313.
37. Neely EK, Hintz RL, Wilson DM, et al. Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr 1995;127:40-46.
38. Albrecht L, Styne D. Laboratory testing of gonadal steroids in children. Pediatr Endocrinol Rev 2007;5:599-607.
39. Resende EA, Lara BH, Reis JD, et al. Assessment of basal and gonadotropinreleasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab 2007;92:1424-1429.
40. Neely EK, Wilson DM, Lee PA, et al. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr 1995;127:47-52.
41. Bordini B, Littlejohn E, Rosenfield RL. Blunted sleep-related luteinizing hormone rise in healthy premenarcheal pubertal girls with elevated body mass index. J Clin Endocrinol Metab 2009;94:1168-1175.
42. Sathasivam A, Garibaldi L, Shapiro S, et al. Leuprolide stimulation testing for the evaluation of early female sexual maturation. Clin Endocrinol 2010;73:375-381.
43. Chi CH, Durham E, Neely EK. Pharmacodynamics of aqueous leuprolide acetate stimulation testing in girls: correlation between clinical diagnosis and time of peak luteinizing hormone level. J Pediatr 2012;61:757-759.
44. Sathasivam A, Rosenberg HK, Shapiro S, et al. Pelvic ultrasonography in the evaluation of central precocious puberty: comparison with leuprolide stimulation test. J Pediatr 2011;159:490-495.
45. Battaglia C, Mancini F, Regnani G, et al. Pelvic ultrasound and color Doppler findings in different isosexual precocities. Ultrasound Obstet Gynecol 2003;22:277-283.
46. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752-e762.
47. Bertelloni S, Baroncelli GI. Current pharmacotherapy of central precocious puberty by GnRH analogs: certainties and uncertainties. Expert Opin Pharmacother 2013;14:1627-1639.
48. Neely EK, Lee PA, Bloch CA, et al. Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol 2010;2010:398639.
49. Lee PA, Neely EK, Fuqua J, et al. Efficacy of leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol 2011;2011:7.
50. Badaru A, Wilson DM, Bachrach LK, et al. Sequential comparisons of onemonth and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006;91:1862-1867.
51. Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr 2011;159:982-987.
52. Lee PA, Klein K, Mauras N, et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab 2012;97:1572-1580.
53. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab 2007;92:1697-1704.
54. Rahhal S, Clarke WL, Kletter GB, et al. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol 2009;2009:812517.
55. Lewis KA, Goldyn AK, West KW, Eugster EA. A single histrelin implant is effective for 2 years for treatment of central precocious puberty. J Pediatr 2013;163:1214-1216.
56. Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics 2002;109:E30.
57. Brito VN, Latronico AC, Arnhold IJ, Mendonca BB. A single luteinizing hormone determination 2 hafter depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls. J Clin Endocrinol Metab 2004;89:4338-4342.
58. Lewis KA, Eugster EA. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty. J Pediatr 2013;162:562-565.
59. Neely EK, Silverman LA, Geffner ME, et al. Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy. Int J Pediatr Endocrinol 2013;2013:20.
60. Thornton P, Silverman LA, Geffner ME, et al. Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty. Pediatr Endocrinol Rev 2014;11:306-317. A good review of therapeutic outcomes.
61. Klein KO, Barnes KM, Jones JV, et al. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001;86:4711-4716.
62. Pasquino AM, Pucarelli I, Accardo F, et al. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008;93:190-195.
63. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 2007;92:3483-3489.
64. Cassio A, Cacciari E, Balsamo A, et al. Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch Dis Child 1999;81:329-332.
65. Downing J, Bellis MA. Early pubertal onset and its relationship with sexual risk taking, substance use and antisocial behaviour: a preliminary cross-sectional study. BMC Public Health 2009;9:446.
66. Blumenthal H, Leen-Feldner EW, Babson KA, et al. Elevated social anxiety among early maturing girls. Dev Psychol 2011;47:1133-1140.
67. Colmenares A, Gunczler P, Lanes R. Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment. Intl J Pediatr Endocrinol 2014;2014:5.
68. Arrigo T, De Luca F, Antoniazzi F, et al. Menstrual cycle pattern during the first gynaecological years in girls with precocious puberty following gonadotropinreleasing hormone analogue treatment. Eur J Pediatr 2007;166:73-74.
69. Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf) 2004;61:626-634.
70. Poomthavorn P, Suphasit R, Mahachoklertwattana P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment. Gynecol Endocrinol 2011;27:524-528.
71. Gillis D, Karavani G, Hirsch HJ, Strich D. Time to menarche and final height after histrelin implant treatment for central precocious puberty. J Pediatr 2013;163:532-536.
72. Heger S, Muller M, Ranke M, et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol 2006;254-255:217-217.
73. Chiavaroli V, Liberati M, D'Antonio F, et al. GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome. Eur J Endocrinol 2010;163:55-62.
74. Franceschi R, Gaudino R, Marcolongo A, et al. Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty. Fertil Steril 2010;93:1185-1191.
75. Magiakou MA, Manousaki D, Papadaki M, et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 2010;95:109-117.
76. Cassio A, Bal MO, Orsini LF, et al. Reproductive outcome in patients treated and not treated for idiopathic early puberty: long-term results of a randomized trial in adults. J Pediatr 2006;149:532-536.